Equities analysts expect Mirati Therapeutics, Inc. (NASDAQ:MRTX) to post earnings per share (EPS) of ($0.81) for the current quarter, according to Zacks. Zero analysts have provided estimates for Mirati Therapeutics’ earnings, with estimates ranging from ($0.87) to ($0.74). Mirati Therapeutics reported earnings per share of ($1.11) in the same quarter last year, which suggests a positive year over year growth rate of 27%. The company is scheduled to issue its next earnings report on Thursday, August 3rd.

According to Zacks, analysts expect that Mirati Therapeutics will report full year earnings of ($3.21) per share for the current year, with EPS estimates ranging from ($3.36) to ($2.99). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.42) per share, with EPS estimates ranging from ($2.61) to ($2.27). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Mirati Therapeutics.

A number of analysts recently weighed in on the stock. ValuEngine cut shares of Mirati Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Jefferies Group LLC reiterated a “hold” rating and set a $5.50 price target on shares of Mirati Therapeutics in a research note on Wednesday, April 12th. Finally, Zacks Investment Research upgraded shares of Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $7.54.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/24/0-81-earnings-per-share-expected-for-mirati-therapeutics-inc-nasdaqmrtx-this-quarter.html.

A number of hedge funds have recently modified their holdings of MRTX. KCG Holdings Inc. acquired a new stake in shares of Mirati Therapeutics during the first quarter worth $106,000. Trexquant Investment LP increased its position in shares of Mirati Therapeutics by 62.2% in the first quarter. Trexquant Investment LP now owns 42,879 shares of the biotechnology company’s stock worth $223,000 after buying an additional 16,447 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after buying an additional 11,753 shares during the last quarter. Omega Advisors Inc. purchased a new position in shares of Mirati Therapeutics during the first quarter worth approximately $520,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Mirati Therapeutics during the first quarter worth approximately $677,000. Hedge funds and other institutional investors own 64.60% of the company’s stock.

Shares of Mirati Therapeutics (MRTX) traded up 1.02% on Monday, hitting $4.95. 155,021 shares of the company traded hands. Mirati Therapeutics has a 12 month low of $2.70 and a 12 month high of $7.22. The company’s market capitalization is $123.45 million. The stock’s 50-day moving average price is $3.58 and its 200-day moving average price is $4.58.

Get a free copy of the Zacks research report on Mirati Therapeutics (MRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.